Sema4 Holdings Corp.: directors' dealings · United States · SEC (Form 4)

About Sema4 Holdings Corp.

Sema4 Holdings Corp. (ticker SMFR) was a U.S.-listed company traded on the NASDAQ market in the United States. For investors following SEC Form 4 insider transactions, the company is best understood as a genomics- and data-driven healthcare business that emerged from a business combination between CM Life Sciences, a SPAC formed in 2020, and the legacy Sema4 platform, which traces back to Mount Sinai Genomics. Following the merger, the business adopted the Sema4 Holdings Corp. name and began trading on NASDAQ under SMFR on July 23, 2021. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1818331/000162828022007480/sema4-424b3.htm?utm_source=openai)) Operationally, Sema4 was positioned in genomics-related diagnostic and information services. Its core activity combined laboratory testing, clinical interpretation, and health-data analytics intended to support better medical decisions. The company also described a research-oriented mission in genomics, placing it at the intersection of diagnostics, precision medicine, and clinical data infrastructure. That mix made Sema4 more than a traditional lab operator: it aimed to monetize both testing workflows and the analytical value embedded in health data. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1818331/000181833122000072/a424b3-smfrx20220630x10q1.htm?utm_source=openai)) From an investment perspective, the filings show that Sema4 operated with the economic profile typical of an early-stage, growth-focused healthcare platform. The company reported substantial net losses, negative operating cash flow, and the need for additional capital to fund ongoing operations and future expansion. In practical terms, this means the equity story was driven less by near-term profitability and more by the ability to scale testing volumes, extend product offerings, and improve unit economics over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1818331/000181833122000050/smfr-20220331x10q424b32.htm?utm_source=openai)) In competitive terms, Sema4 participated in a crowded U.S. market for genetic diagnostics and specialized laboratory services. Its differentiator was the combination of genomics expertise with a data analytics layer designed for precision medicine use cases. That created a potentially attractive niche, but it also exposed the business to intense competition from larger, better-capitalized diagnostic peers with broader commercial reach and stronger balance sheets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1818331/000181833122000072/a424b3-smfrx20220630x10q1.htm?utm_source=openai)) Geographically, the company was organized in the United States and its public-market listing was on NASDAQ, which is important for investors screening U.S. healthcare equities. Public filings indicate a primarily domestic operating footprint, consistent with a diagnostics company serving the U.S. healthcare system. The information available in SEC documents also reflects a corporate ecosystem tied to New York-based sponsor and ownership structures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1478815/000089924322016474/xslF345X03/doc4.xml?utm_source=openai)) A key recent corporate development is that the former Sema4 later became GeneDx Holdings Corp., according to SEC materials. For market participants, that matters because SMFR is tied to the company’s earlier listed identity rather than its later post-transition name. In other words, the ticker SMFR belongs to the Sema4 chapter of the business history, while the current corporate identity has moved on. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1818331/000181833124000027/arsgenedx-2023x1231x10xk.pdf?utm_source=openai))